Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:ULBI - Ultralife Stock Price, Forecast & News

$7.20
-0.07 (-0.96 %)
(As of 01/23/2020 06:00 AM ET)
Today's Range
$6.85
Now: $7.20
$7.32
50-Day Range
$7.20
MA: $7.50
$8.37
52-Week Range
$6.85
Now: $7.20
$11.97
Volume22,070 shs
Average Volume13,741 shs
Market Capitalization$114.17 million
P/E Ratio5.00
Dividend YieldN/A
Beta0.86
Ultralife Corporation designs, manufactures, installs, and maintains power, and communication and electronic systems for government, defense, and commercial sectors worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium ion cells, multi-kilowatt module lithium ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables. Read More…

Industry, Sector and Symbol

Industry Miscellaneous electrical machinery, equipment, & supplies
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:ULBI
CUSIPN/A
Phone315-332-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.19 million
Cash Flow$1.69 per share
Book Value$6.55 per share

Profitability

Net Income$24.93 million

Miscellaneous

EmployeesN/A
Market Cap$114.17 million
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive ULBI News and Ratings via Email

Sign-up to receive the latest news and ratings for ULBI and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Ultralife (NASDAQ:ULBI) Frequently Asked Questions

What is Ultralife's stock symbol?

Ultralife trades on the NASDAQ under the ticker symbol "ULBI."

How will Ultralife's stock buyback program work?

Ultralife declared that its Board of Directors has approved a share repurchase program on Thursday, November 1st 2018, which allows the company to repurchase 2,500,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

How were Ultralife's earnings last quarter?

Ultralife Corp. (NASDAQ:ULBI) released its quarterly earnings data on Thursday, October, 31st. The technology company reported $0.07 earnings per share for the quarter. The technology company had revenue of $27.49 million for the quarter. Ultralife had a net margin of 24.12% and a return on equity of 22.91%. View Ultralife's Earnings History.

When is Ultralife's next earnings date?

Ultralife is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Ultralife.

Has Ultralife been receiving favorable news coverage?

Media coverage about ULBI stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultralife earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Ultralife.

Are investors shorting Ultralife?

Ultralife saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 143,000 shares, an increase of 5.1% from the December 15th total of 136,100 shares. Based on an average daily volume of 19,300 shares, the short-interest ratio is presently 7.4 days. Approximately 1.4% of the company's shares are short sold. View Ultralife's Current Options Chain.

Who are some of Ultralife's key competitors?

What other stocks do shareholders of Ultralife own?

Who are Ultralife's key executives?

Ultralife's management team includes the folowing people:
  • Mr. Michael D. Popielec, CEO, Pres & Director (Age 57)
  • Mr. Philip A. Fain, CFO, Treasurer & Corp. Sec. (Age 64)

How do I buy shares of Ultralife?

Shares of ULBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ultralife's stock price today?

One share of ULBI stock can currently be purchased for approximately $7.20.

How big of a company is Ultralife?

Ultralife has a market capitalization of $114.17 million and generates $87.19 million in revenue each year. View Additional Information About Ultralife.

What is Ultralife's official website?

The official website for Ultralife is http://www.ultralifecorp.com/.

How can I contact Ultralife?

Ultralife's mailing address is 2000 TECHNOLOGY PARKWAY, NEWARK NY, 14513. The technology company can be reached via phone at 315-332-7100.


MarketBeat Community Rating for Ultralife (NASDAQ ULBI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Ultralife and other stocks. Vote "Outperform" if you believe ULBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ULBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel